儿童严重急性呼吸综合征冠状病毒 2 感染。
Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Children.
机构信息
Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, 1959 NE Pacific Street, Box 356423, Seattle, WA 98195, USA.
Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Washington, Seattle Children's Research Institute, 4800 Sand Point Way NE - MA7.234, Seattle, WA 98105, USA.
出版信息
Infect Dis Clin North Am. 2022 Jun;36(2):435-479. doi: 10.1016/j.idc.2022.01.005. Epub 2022 Feb 1.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in children generally have milder presentations, but severe disease can occur in all ages. MIS-C and persistent post-acute COVID-19 symptoms can be experienced by children with previous infection and emphasize the need for infection prevention. Optimal treatment for COVID-19 is not known, and clinical trials should include children to guide therapy. Vaccines are the best tool at preventing infection and severe outcomes of COVID-19. Children suffered disproportionately during the pandemic not only from SARS-CoV-2 infection but because of disruptions to daily life, access to primary care, and worsening income inequalities.
摘要
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染在儿童中通常表现较轻，但所有年龄段都可能发生严重疾病。患有既往感染的儿童可出现儿童多系统炎症综合征（MIS-C）和持续的急性新冠后 COVID-19 症状，这强调了感染预防的必要性。目前尚不清楚 COVID-19 的最佳治疗方法，临床试验应包括儿童以指导治疗。疫苗是预防 COVID-19 感染和严重后果的最佳工具。儿童在大流行期间不仅因 SARS-CoV-2 感染而遭受不成比例的影响，还因日常生活中断、获得初级保健的机会减少以及收入不平等加剧而受到影响。
相似文献
1
Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Children.儿童严重急性呼吸综合征冠状病毒 2 感染。
Infect Dis Clin North Am. 2022 Jun;36(2):435-479. doi: 10.1016/j.idc.2022.01.005. Epub 2022 Feb 1.
2
Human and novel coronavirus infections in children: a review.儿童人感染和新型冠状病毒感染：综述。
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
3
Multisystem Inflammatory Syndrome in Children after SARS-CoV-2 Vaccination.儿童接种 SARS-CoV-2 疫苗后的多系统炎症综合征。
Emerg Infect Dis. 2022 May;28(5):990-993. doi: 10.3201/eid2805.212418. Epub 2022 Mar 11.
4
SARS-CoV-2 Infection and Racial Disparities in Children: Protective Mechanisms and Severe Complications Related to MIS-C.SARS-CoV-2 感染与儿童中的种族差异：与 MIS-C 相关的保护机制和严重并发症。
J Racial Ethn Health Disparities. 2022 Aug;9(4):1536-1542. doi: 10.1007/s40615-021-01092-7. Epub 2021 Jul 13.
5
Update on SARS-CoV-2 infection in children.儿童 SARS-CoV-2 感染最新情况。
Paediatr Int Child Health. 2021 Feb;41(1):56-64. doi: 10.1080/20469047.2021.1888026. Epub 2021 Feb 22.
6
Children with SARS-CoV-2 infection during the novel coronaviral disease (COVID-19) outbreak in Iran: an alarming concern for severity and mortality of the disease.伊朗新型冠状病毒病（COVID-19）疫情期间感染 SARS-CoV-2 的儿童：对疾病严重程度和死亡率的令人震惊的关注。
BMC Infect Dis. 2022 Apr 15;22(1):382. doi: 10.1186/s12879-022-07200-0.
7
COVID-19 in Pediatrics.儿童 COVID-19 。
Rheum Dis Clin North Am. 2021 Nov;47(4):797-811. doi: 10.1016/j.rdc.2021.07.006. Epub 2021 Jul 21.
8
SARS-CoV-2-specific T cell responses in patients with multisystem inflammatory syndrome in children.儿童多系统炎症综合征患者中的 SARS-CoV-2 特异性 T 细胞应答。
Clin Immunol. 2022 Oct;243:109106. doi: 10.1016/j.clim.2022.109106. Epub 2022 Aug 30.
9
Measurement of Severe Acute Respiratory Syndrome Coronavirus 2 Antigens in Plasma of Pediatric Patients With Acute Coronavirus Disease 2019 or Multisystem Inflammatory Syndrome in Children Using an Ultrasensitive and Quantitative Immunoassay.使用超敏定量免疫分析法检测急性冠状病毒病 2019 或儿童多系统炎症综合征患儿血浆中严重急性呼吸综合征冠状病毒 2 抗原。
Clin Infect Dis. 2022 Oct 12;75(8):1351-1358. doi: 10.1093/cid/ciac160.
10
COVID-19-Related Multi-systemic Inflammatory Syndrome in Children (MIS-C).儿童 COVID-19 相关多系统炎症综合征（MIS-C）。
Adv Exp Med Biol. 2024;1448:409-425. doi: 10.1007/978-3-031-59815-9_28.
引用本文的文献
1
Clinical Outcomes of Pediatric Cancer Patients with COVID-19: A Cross-Sectional Study.新冠肺炎患儿癌症患者的临床结局：一项横断面研究。
Int J Hematol Oncol Stem Cell Res. 2024 Oct 1;18(4):313-322. doi: 10.18502/ijhoscr.v18i4.16756.
2
Spectrum of severity of multisystem inflammatory syndrome in children: an EHR-based cohort study from the RECOVER program.多系统炎症综合征儿童严重程度谱：RECOVER 项目基于电子病历的队列研究。
Sci Rep. 2023 Nov 28;13(1):21005. doi: 10.1038/s41598-023-47655-y.
3
Effect of the COVID-19 pandemic on the pediatric infectious disease landscape.新冠疫情对儿童传染病格局的影响。
Eur J Pediatr. 2024 Mar;183(3):1001-1009. doi: 10.1007/s00431-023-05210-x. Epub 2023 Sep 20.
4
Acceptability and Feasibility of Saliva-delivered PCR Coronavirus 2019 Tests for Young Children.唾液PCR 新冠病毒 2019 检测在幼儿中的可接受性和可行性。
Pediatrics. 2023 Jul 1;152(Suppl 1). doi: 10.1542/peds.2022-060352D.
5
Editorial: COVID-19 and hyper inflammation syndrome: Different presentation and management.社论：2019冠状病毒病与高炎症综合征：不同的表现与管理
Front Pediatr. 2022 Sep 9;10:1022701. doi: 10.3389/fped.2022.1022701. eCollection 2022.
6
Anti-SARS-CoV-2 antibodies in breast milk during lactation after infection or vaccination: A cohort study.哺乳期感染或接种疫苗后母乳中的抗 SARS-CoV-2 抗体：一项队列研究。
J Reprod Immunol. 2022 Sep;153:103685. doi: 10.1016/j.jri.2022.103685. Epub 2022 Aug 4.
7
Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years.BNT162b2 疫苗在预防 12 至 17 岁青少年因德尔塔和奥密克戎变异株感染而前往急诊科和紧急护理中心就诊方面的有效性。
JAMA Netw Open. 2022 Aug 1;5(8):e2225162. doi: 10.1001/jamanetworkopen.2022.25162.
8
Myocardial Infarction in Children after COVID-19 and Risk Factors for Thrombosis.新冠病毒感染后儿童的心肌梗死及血栓形成的危险因素
Diagnostics (Basel). 2022 Apr 1;12(4):884. doi: 10.3390/diagnostics12040884.
本文引用的文献
1
Characterising approaches to steroid therapy in paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2.描述与SARS-CoV-2暂时相关的儿童多系统炎症综合征中类固醇治疗的方法。
J Paediatr Child Health. 2023 Jul;59(7):890-894. doi: 10.1111/jpc.16408. Epub 2023 Apr 28.
2
Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021.辉瑞-生物科技的 BNT162b2 (Pfizer-BioNTech) mRNA 疫苗在 12-18 岁人群中预防儿童多系统炎症综合征的有效性-美国，2021 年 7 月至 12 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 14;71(2):52-58. doi: 10.15585/mmwr.mm7102e1.
3
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.广谱中和抗体可克服 SARS-CoV-2 奥密克戎抗原漂移。
Nature. 2022 Feb;602(7898):664-670. doi: 10.1038/s41586-021-04386-2. Epub 2021 Dec 23.
4
School Learning Format and Children's Behavioral Health During the COVID-19 Pandemic.学校学习模式与新冠疫情期间儿童的行为健康
JAMA Pediatr. 2022 Apr 1;176(4):410-411. doi: 10.1001/jamapediatrics.2021.5698.
5
Evaluation of Test to Stay Strategy on Secondary and Tertiary Transmission of SARS-CoV-2 in K-12 Schools - Lake County, Illinois, August 9-October 29, 2021.评价 K-12 学校中 SARS-CoV-2 二次和三次传播的 Test to Stay 策略 - 伊利诺伊州莱克县，2021 年 8 月 9 日至 10 月 29 日。
MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1778-1781. doi: 10.15585/mmwr.mm705152e2.
6
Characteristics and Clinical Outcomes of Children and Adolescents Aged <18 Years Hospitalized with COVID-19 - Six Hospitals, United States, July-August 2021.2021 年 7-8 月，美国六家医院收治的<18 岁儿童和青少年 COVID-19 患者的特征和临床结局。
MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1766-1772. doi: 10.15585/mmwr.mm705152a3.
7
Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021.辉瑞-生物技术公司（Pfizer-BioNTech）疫苗 BNT162b2 对预防 12-17 岁青少年感染 SARS-CoV-2 的疫苗有效性的临时估计-亚利桑那州，2021 年 7 月至 12 月。
MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1761-1765. doi: 10.15585/mmwr.mm705152a2.
8
Evaluation of a Test to Stay Strategy in Transitional Kindergarten Through Grade 12 Schools - Los Angeles County, California, August 16-October 31, 2021.评估过渡幼儿园至 12 年级学校中的“Test to Stay”策略 - 加利福尼亚州洛杉矶县，2021 年 8 月 16 日至 10 月 31 日。
MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1773-1777. doi: 10.15585/mmwr.mm705152e1.
9
COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021.2021 年 11 月 3 日至 12 月 19 日，美国 5-11 岁儿童的 COVID-19 疫苗安全性。
MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1755-1760. doi: 10.15585/mmwr.mm705152a1.
10
Relative instantaneous reproduction number of Omicron SARS-CoV-2 variant with respect to the Delta variant in Denmark.丹麦的奥密克戎（Omicron） SARS-CoV-2 变体相对于德尔塔（Delta）变体的相对瞬时繁殖数。
J Med Virol. 2022 May;94(5):2265-2268. doi: 10.1002/jmv.27560. Epub 2022 Jan 11.
Zotero 插件